Skip to main content

Table 1 Detailed inclusion and exclusion criteria regarding the type of study, age, intervention and outcomes

From: Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults – a systematic review

Criteria Inclusion Exclusion
Type of study SR &MA RCT OS editorials, opinion papers, case reports, case series, narrative reviews, letters, qualitative studies and observational studies which do not provide information of interest regarding adverse events
Age of participants mean or median age ≥ 65 years, or subgroup analysis ≥ 65 years ≥ 80% of participants ≥ 65 years or a subgroup analysis ≥ 65 years  
Type of intervention efficacy and/or safety of PAI as monotherapy or in combination with any other drug for the treatment or prevention of cerebral infarction, transient ischaemic attacks, peripheral artery occlusive disease and coronary disease or one of these indications versus placebo, no treatment, other drugs or a non-pharmacological intervention focus on acute conditions (like exclusively acute treatment of myocardial infarction during the first hours)
Clinically relevant outcomes quality of life, mortality, life expectancy, hospitalization, cognitive impairment or cognitive status, functional impairment or functional status, cardiovascular event including stroke, renal failure, composite end points including any of the above (extraction of individual outcomes will be done if reported by original studies), adverse drug event, bleeding surrogate endpoints (like laboratory measurements or blood pressure)
  1. MA meta-analysis, OS observational study, RCT randomised controlled trial, SR systematic review